Design
Review
Authors
Loading...
Targeted ROS modulation may preserve beneficial NO in HF; leaves open whether this improves clinical outcomes.
Key points are not available for this paper at this time.
Hajime Otani (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: